Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
One of them, glucagon-like peptide (GLP)-1, has glucose-lowering properties [4, 5] and has been the basis of two novel classes of glucose-lowering agents, incretin mimetics (i.e
Ongoing research continues to refine our understanding of these medications
Place your right palm on the bench
GLP-1 is also secreted by a small population of neurons in the hindbrain (Richard et al., 2015)
There was no difference between the groups in the number of procedural complications or adverse events
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
US$ 28.77
US$ 23.62
US$ 24.84
US$ 21.76
US$ 28.73
US$ 23.11
